I am currently going through red skin syndrome/topical steroid withdrawal. The only cure as of now is time(6 months to 3 years) and waiting out horrible eczema-like flares. My main issue is burning/tingling skin that is almost constant. Steroids close off blood vessels and when you stop them they 'wake' up causing this nerve discomfort/pain. I've been smoking medical cannabis for the duration of my recovery(1.5 years) and It's done wonders except that the flare is around my mouth and I'm afraid the smoking is causing more issues.. as well as helping. I need to step up my game and take a different approach. I am wondering how to go about using cbd but I don't know where to start and was wondering if you could help. Thank you
In late 2017, researchers with the University of Guelph in Canada published the first-ever study to document the ideal growing conditions for cannabis. Using liquid organic fertilizer with a PKN ratio of 1.3P–1.7K-4.0N, the experiment tested five increasing rates of fertilization. They also tested two coir-based soil-less growing media, or “substrates.”
If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Cannabis and Cannabinoids (PDQ®)–Health Professional Version was originally published by the National Cancer Institute.”
Cannabis sativa is extremely unusual in the diversity of products for which it is or can be cultivated. Popular Mechanics magazine (1938) touted hemp as “the new billion dollar crop,” stating that it “can be used to produce more than 25,000 products, ranging from dynamite to Cellophane.” Table 1 presents the principal products for which the species is cultivated in Europe, all of which happen to be based on fiber. This presentation stresses the products that hold the most promise for North America, which also include a considerable range of oilseed applications (Table 2; Fig. 1).
Another Israeli group postulated that the anti-inflammatory and immunosuppressive effects of CBD might make it a valuable adjunct in the treatment of acute graft-versus-host disease (GVHD) in patients who have undergone allogeneic hematopoietic stem cell transplantation. The authors investigated CBD 300 mg/d in addition to standard GVHD prophylaxis in 48 adult patients who had undergone transplantation predominantly for acute leukemia or myelodysplastic syndrome (NCT01385124 and NCT01596075). The combination of CBD with standard GVHD prophylaxis was found to be safe. Compared with 101 historical controls treated with standard prophylaxis, patients who received CBD appeared to have a lower incidence of grade II to grade IV GVHD, suggesting that a randomized controlled trial (RCT) is warranted.
Dr. Ethan Russo, medical director at Phytecs, a biotechnology company spearheading research into plant- based medicines and the endocannabinoid system, took issue with Titus’s claim, however. “Bioaccumulators can recruit heavy metals from the soil,” Russo said, “but breaking them down would be alchemy.” Government regulation of the pharmaceutical industry is designed to protect consumers from unfounded scientific claims.
Despite advances in pharmacologic and nonpharmacologic management, nausea and vomiting (N/V) remain distressing side effects for cancer patients and their families. Dronabinol, a synthetically produced delta-9-THC, was approved in the United States in 1986 as an antiemetic to be used in cancer chemotherapy. Nabilone, a synthetic derivative of delta-9-THC, was first approved in Canada in 1982 and is now also available in the United States. Both dronabinol and nabilone have been approved by the U.S. Food and Drug Administration (FDA)for the treatment of N/V associated with cancer chemotherapy in patients who have failed to respond to conventional antiemetic therapy. Numerous clinical trials and meta-analyses have shown that dronabinol and nabilone are effective in the treatment of N/V induced by chemotherapy.[25-28] The National Comprehensive Cancer Network Guidelines recommend cannabinoids as breakthrough treatment for chemotherapy-related N/V. The American Society for Clinical Oncology (ASCO) antiemetic guidelines updated in 2017 recommends that the FDA-approved cannabinoids, dronabinol or nabilone, be used to treat N/V that is resistant to standard antiemetic therapies.
Van Roekel (1994) has pointed out that Egyptian papyrus sheets are not “paper,” because the fiber strands are woven, not “wet-laid;” the oldest surviving paper is over 2,000 years of age, from China, and was made from hemp fiber (Fleming and Clarke 1998). Until the early 19th century, hemp, and flax were the chief paper-making materials. In historical times, hemp rag was processed into paper. Using hemp directly for paper was considered too expensive, and in any event the demand for paper was far more limited than today. Wood-based paper came into use when mechanical and chemical pulping was developed in the mid 1800s in Germany and England. Today, at least 95% of paper is made from wood pulp.
In the mid 1990s, the EU provided subsidization for hemp cultivation of ca. $1,050/ha. This support was instrumental in developing a hemp industry in western Europe. However, no comparable support is available in North America, and indeed those contemplating entering into hemp cultivation are faced with extraordinary costs and/or requirements in connection with licensing, security, THC analysis, and record keeping. Those involved in value-added processing and distribution are also faced with legal uncertainties and the regular threat of idiosyncratic, indeed irrational actions of various governments. Simply displaying a C. sativa leaf on advertising has led to the threat of criminal charges in the last decade in several G8 countries. Attempting to export or import hemp products among countries is presently a most uncertain activity.
Cannabis is believed to be an aggravating factor in rare cases of arteritis, a serious condition that in some cases leads to amputation. Because 97% of case-reports also smoked tobacco, a formal association with cannabis could not be made. If cannabis arteritis turns out to be a distinct clinical entity, it might be the consequence of vasoconstrictor activity observed from delta-8-THC and delta-9-THC. Other serious cardiovascular events including myocardial infarction, stroke, sudden cardiac death, and cardiomyopathy have been reported to be temporally associated with cannabis use. Research in these events is complicated because cannabis is often used in conjunction with tobacco, and drugs such as alcohol and cocaine. These putative effects can be taken in context of a wide range of cardiovascular phenomena regulated by the endocannabinoid system and an overall role of cannabis in causing decreased peripheral resistance and increased cardiac output, which potentially could pose a threat to those with cardiovascular disease. There is some evidence from case reports that cannabis use may provoke fatal cardiovascular events in young people who have not been diagnosed with cardiovascular disease. Smoking cannabis has also been shown to increase the risk of myocardial infarction by 4.8 times for the 60 minutes after consumption.
Although cannabis as a drug and industrial hemp both derive from the species Cannabis sativa and contain the psychoactive component tetrahydrocannabinol (THC), they are distinct strains with unique phytochemical compositions and uses. Hemp has lower concentrations of THC and higher concentrations of cannabidiol (CBD), which decreases or eliminates its psychoactive effects. The legality of industrial hemp varies widely between countries. Some governments regulate the concentration of THC and permit only hemp that is bred with an especially low THC content.